89bio, Inc. financial data

Symbol
ETNB on Nasdaq
Industry
Pharmaceutical Preparations
Location
142 Sansome Street, Second Floor, San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.48K % -9.83%
Debt-to-equity 14.1 % +5.68%
Return On Equity -59.6 % -70.7%
Return On Assets -52.2 % -69.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 106M shares +40.3%
Common Stock, Shares, Outstanding 106M shares
Entity Public Float 1.18B USD +3767%
Common Stock, Value, Issued 106K USD +41.3%
Weighted Average Number of Shares Outstanding, Basic 107M shares +40.3%
Weighted Average Number of Shares Outstanding, Diluted 107M shares +40.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 267M USD +148%
General and Administrative Expense 36.5M USD +32.1%
Operating Income (Loss) -304M USD -124%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -285M USD -125%
Income Tax Expense (Benefit) 4.3M USD
Net Income (Loss) Attributable to Parent -289M USD -128%
Earnings Per Share, Basic -2.9 USD/shares -110%
Earnings Per Share, Diluted -2.9 USD/shares -110%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 91.4M USD -63.7%
Marketable Securities, Current 332M USD
Cash, Cash Equivalents, and Short-term Investments 424M USD -5.47%
Assets, Current 456M USD -0.72%
Property, Plant and Equipment, Net 17K USD -70.7%
Operating Lease, Right-of-Use Asset 1.76M USD +639%
Other Assets, Noncurrent 314K USD +8.65%
Assets 458M USD -0.39%
Accounts Payable, Current 19.5M USD +78.8%
Employee-related Liabilities, Current 5.25M USD +33.4%
Accrued Liabilities, Current 18.9M USD +33.7%
Liabilities, Current 39.1M USD +55.2%
Operating Lease, Liability, Noncurrent 1.28M USD +2317%
Other Liabilities, Noncurrent 3.75M USD
Liabilities 80.2M USD +60.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.27M USD
Retained Earnings (Accumulated Deficit) -706M USD -69.3%
Stockholders' Equity Attributable to Parent 378M USD -7.83%
Liabilities and Equity 458M USD -0.39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.7M USD -32%
Net Cash Provided by (Used in) Financing Activities 21M USD -93.5%
Net Cash Provided by (Used in) Investing Activities -79.9M USD -2046%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 106M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -98.6M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 91.4M USD -63.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 679K USD +25.3%
Deferred Tax Assets, Valuation Allowance 108M USD +42.4%
Deferred Tax Assets, Gross 109M USD +42.8%
Operating Lease, Liability 2.31M USD +553%
Depreciation 9K USD -35.7%
Payments to Acquire Property, Plant, and Equipment 6K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -287M USD -127%
Lessee, Operating Lease, Liability, to be Paid 2.87M USD +661%
Operating Lease, Liability, Current 743K USD +322%
Lessee, Operating Lease, Liability, to be Paid, Year Two 917K USD +396%
Lessee, Operating Lease, Liability, to be Paid, Year One 774K USD +318%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 555K USD +2313%
Lessee, Operating Lease, Liability, to be Paid, Year Three 937K USD +13286%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 12.1M USD +664%
Lessee, Operating Lease, Liability, to be Paid, Year Four 240K USD
Additional Paid in Capital 1.08B USD
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 7K USD -72%
Deferred Tax Assets, Net of Valuation Allowance 715K USD +124%
Share-based Payment Arrangement, Expense 19.5M USD +31.3%
Operating Leases, Future Minimum Payments Due 105K USD -33.5%
Interest Expense 4.97M USD +11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%